Free Trial
→ What’s Elon building now? (From Paradigm Press) (Ad)tc pixel
NASDAQ:RGNX

REGENXBIO Q3 2026 Earnings Date & Estimates

REGENXBIO logo
$8.07 -0.02 (-0.25%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$8.14 +0.07 (+0.92%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

REGENXBIO is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from REGENXBIO in Q3 2026

REGENXBIO is expected to post earnings of -$1.2992 per share on revenue of $14.87 million. In the same quarter a year earlier REGENXBIO reported -$1.20 per share on revenue of $29.73 million. REGENXBIO last reported on August 6, 2026, posting $0.43 per share and beating the $0.0787 consensus estimate. REGENXBIO has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.2992
Expected Revenue
$14.87 million
Prior-Year EPS
-$1.20
Prior-Year Revenue
$29.73 million
Expected Revenue Growth
-50.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.43 (Beat by +$0.3513)
Last Quarter Revenue
$108.02 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

REGENXBIO Q3 2026 Earnings FAQ

REGENXBIO (NASDAQ:RGNX) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

REGENXBIO's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect REGENXBIO to post earnings of -$1.2992 per share for Q3 2026.

The consensus revenue estimate for REGENXBIO is $14.87 million for Q3 2026.

REGENXBIO Earnings Headlines

REGENXBIO (NASDAQ:RGNX) Stock Rating Raised to Strong-Buy at Mizuho
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091283
Mizuho initiates coverage of REGENXBIO at outperform
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/mizuho-initiates-coverage-of-regenxbio-at-outperform/ar-AA2dDh2d
What’s Elon building now?
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.tc pixel
October 10 at 1:00 AM  |  Paradigm Press (Ad)
REGENXBIO (NASDAQ:RGNX) Stock Jumps 8.1% - What's Next?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087857
Mizuho Initiates REGENXBIO at Outperform With $22 Price Target
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/mizuho-initiates-regenxbio-outperform-22-100219548.html
Regenxbio’s two lead gene therapies back Mizuho’s nearly 200% upside call
October 5, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/regenxbio-s-two-lead-gene-therapies-back-mizuho-s-nearly-200-upside-call/ar-AA2dAXQA
See More REGENXBIO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like REGENXBIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on REGENXBIO and other key companies, straight to your email.

About REGENXBIO

REGENXBIO (NASDAQ:RGNX) is a biotechnology company focused on developing and commercializing gene therapies for serious diseases. The company’s programs are based primarily on its proprietary NAV AAV Technology Platform, which uses adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells. Its research has emphasized conditions affecting the central nervous system, muscles and other tissues.

REGENXBIO’s pipeline has included investigational therapies such as RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I and RGX-202 for Duchenne muscular dystrophy. The company also pursues partnerships and licensing arrangements that extend the use of its AAV technology in additional gene therapy programs. Its platform contributed technology to Zolgensma, a gene therapy developed by Novartis for spinal muscular atrophy.

Founded in 2009 and headquartered in Rockville, Maryland, REGENXBIO conducts research and clinical development activities intended for patients in the United States and international markets. The company is led by President and Chief Executive Officer Kenneth T. Mills and works with biotechnology and pharmaceutical partners to advance gene therapy candidates toward potential commercialization.

View REGENXBIO Profile
Earnings Tools